Yayın:
Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients

Basit Görünüm
dc.contributor.buuauthorÇelebi, Solmaz
dc.contributor.buuauthorHacımustafaoğlu, Mustafa Kemal
dc.contributor.buuauthorKöksal, Nilgün
dc.contributor.buuauthorÖzkan, Hilal
dc.contributor.buuauthorÇetinkaya, Merih
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.contributor.researcheridAAG-8393-2021
dc.contributor.scopusid7006095295
dc.contributor.scopusid6602154166
dc.contributor.scopusid7003323615
dc.contributor.scopusid16679325400
dc.contributor.scopusid23994946300
dc.date.accessioned2021-12-20T06:39:12Z
dc.date.available2021-12-20T06:39:12Z
dc.date.issued2010-06
dc.description.abstractAim: The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug-resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children. Methods: Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug-resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50-75 x 103 U/kg per day was given i.v. divided into three doses. Results: Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator-associated pneumonia (n = 14), catheter-related sepsis (n = 1) and skin and soft-tissue infection (n = 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days-15 years) and 60% were male. Mortality was 26.6%. Conclusion: Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug-resistant P. aeruginosa or A. baumannii in pediatric patients.
dc.identifier.citationÇelebi, S. vd. (2010). "Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients". Pediatrics International, 52(3), 410-414.
dc.identifier.endpage414
dc.identifier.issn1328-8067
dc.identifier.issn1442-200X
dc.identifier.issue3
dc.identifier.pubmed20003141
dc.identifier.scopus2-s2.0-77953635339
dc.identifier.startpage410
dc.identifier.urihttps://doi.org/10.1111/j.1442-200X.2009.03015.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1442-200X.2009.03015.x
dc.identifier.urihttp://hdl.handle.net/11452/23381
dc.identifier.volume52
dc.identifier.wos000278803000029
dc.indexed.wosSCIE
dc.language.isoen
dc.publisherWiley
dc.relation.journalPediatrics International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAcinetobacter baumannii
dc.subjectChildren
dc.subjectColistimethate sodium
dc.subjectNosocomial infection
dc.subjectPseudomonas aeruginosa
dc.subjectVentilator-associated pneumonia
dc.subjectIntensive-care-unit
dc.subjectPseudomonas-aeruginosa
dc.subjectIntravenous colistin
dc.subjectNosocomial infections
dc.subjectRisk-factors
dc.subjectAcinetobacter
dc.subjectPediatrics
dc.subject.emtreeColistimethate
dc.subject.emtreeColistin
dc.subject.emtreeAcinetobacter baumannii
dc.subject.emtreeAcute kidney failure
dc.subject.emtreeAdolescent
dc.subject.emtreeArticle
dc.subject.emtreeBacterium detection
dc.subject.emtreeCatheter infection
dc.subject.emtreeChild
dc.subject.emtreeClinical article
dc.subject.emtreeClinical trial
dc.subject.emtreeCreatinine blood level
dc.subject.emtreeCreatinine clearance
dc.subject.emtreeDrug efficacy
dc.subject.emtreeDrug safety
dc.subject.emtreeFemale
dc.subject.emtreeHospital infection
dc.subject.emtreeHuman
dc.subject.emtreeInfant
dc.subject.emtreeMale
dc.subject.emtreeMortality
dc.subject.emtreeNephrotoxicity
dc.subject.emtreeNeuromuscular blocking
dc.subject.emtreeNewborn
dc.subject.emtreePediatrics
dc.subject.emtreePreschool child
dc.subject.emtreePriority journal
dc.subject.emtreePseudomonas aeruginosa
dc.subject.emtreeSchool child
dc.subject.emtreeSepsis
dc.subject.emtreeSide effect
dc.subject.emtreeSkin infection
dc.subject.emtreeSoft tissue infection
dc.subject.emtreeTreatment duration
dc.subject.emtreeTreatment outcome
dc.subject.emtreeTreatment response
dc.subject.emtreeUniversity hospital
dc.subject.emtreeVentilator associated pneumonia
dc.subject.meshAcinetobacter baumannii
dc.subject.meshAcinetobacter infections
dc.subject.meshAdolescent
dc.subject.meshChild
dc.subject.meshChild, preschool
dc.subject.meshColistin
dc.subject.meshCross infection
dc.subject.meshDose-response relationship, drug
dc.subject.meshDrug administration schedule
dc.subject.meshDrug resistance, multiple, bacterial
dc.subject.meshFemale
dc.subject.meshFollow-up studies
dc.subject.meshHospitals, university
dc.subject.meshHumans
dc.subject.meshInfant
dc.subject.meshInfant, newborn
dc.subject.meshInjections, intravenous
dc.subject.meshIntensive care units, neonatal
dc.subject.meshIntensive care units, pediatric
dc.subject.meshMale
dc.subject.meshMicrobial sensitivity tests
dc.subject.meshProspective studies
dc.subject.meshPseudomonas aeruginosa
dc.subject.meshPseudomonas infections
dc.subject.meshStatistics, nonparametric
dc.subject.meshTreatment outcome
dc.subject.meshTurkey
dc.subject.scopusColistin; Polymyxins; Ventilator Associated Pneumonia
dc.subject.wosPediatrics
dc.titleColistimethate sodium therapy for multidrug-resistant isolates in pediatric patients
dc.typeArticle
dc.wos.quartileQ4
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
local.indexed.atScopus
local.indexed.atWOS

Dosyalar

Lisanslı seri

Şimdi gösteriliyor 1 - 1 / 1
Placeholder
Ad:
license.txt
Boyut:
1.71 KB
Format:
Item-specific license agreed upon to submission
Açıklama
İndir

Koleksiyonlar

İndeksli Yayınlar / Indexed Publications